Author: Marty, Francisco M; Chemaly, Roy F; Mullane, Kathleen M; Lee, Dong-Gun; Hirsch, Hans H; Small, Catherine B; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R; Chien, Jason W; Dadwal, Sanjeet S
Title: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Document date: 2019_12_3
ID: sl45z4i0_21
Snippet: From January 31, 2015, to March 20, 2017, 71 patients were screened for eligibility and 11 were excluded, mostly due to lack of new radiographical abnormalities or inability to confirm lower respiratory tract RSV infection ( Figure 1 ). Sixty patients were randomized, of whom 31 were assigned to presatovir and 29 to placebo; 1 patient randomized to presatovir withdrew consent before receiving study drug. Notable protocol deviations are described .....
Document: From January 31, 2015, to March 20, 2017, 71 patients were screened for eligibility and 11 were excluded, mostly due to lack of new radiographical abnormalities or inability to confirm lower respiratory tract RSV infection ( Figure 1 ). Sixty patients were randomized, of whom 31 were assigned to presatovir and 29 to placebo; 1 patient randomized to presatovir withdrew consent before receiving study drug. Notable protocol deviations are described in Supplemental results.
Search related documents:
Co phrase search for related documents- respiratory tract and study drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- respiratory tract and study drug receive: 1
- rsv infection and study drug: 1, 2
Co phrase search for related documents, hyperlinks ordered by date